NO20091675L - Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer - Google Patents
Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorerInfo
- Publication number
- NO20091675L NO20091675L NO20091675A NO20091675A NO20091675L NO 20091675 L NO20091675 L NO 20091675L NO 20091675 A NO20091675 A NO 20091675A NO 20091675 A NO20091675 A NO 20091675A NO 20091675 L NO20091675 L NO 20091675L
- Authority
- NO
- Norway
- Prior art keywords
- ht2a
- receptors
- drug
- ether derivative
- based double
- Prior art date
Links
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 150000002170 ethers Chemical class 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 3
- 206010013663 drug dependence Diseases 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 101150104779 HTR2A gene Proteins 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 206010033864 Paranoia Diseases 0.000 abstract 1
- 208000027099 Paranoid disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Foreliggende oppfinnelse angår duale modulatorer av serotonin 5-HT2a og dopamin D3 reseptorer som er representert ved den generelle formel (I) hvor R1, R2 og A er som definert i beskrivelsen, en fremgangsmåte for fremstilling derav, så vel som farmasøytisk akseptable salter derav for fremstilling av et medikament for behandling eller forebygging av kognitive lidelser, medikament-tilvenning, depresjon, angst, medikament-avhengighet, demens, hukommelsessvikt, psykotiske lidelser omfattende schizofreni, schizoaffektive lidelser, bipolar sykdom, mani, psykotisk depresjon og psykoser omfattende paranoia og tvangsforestillinger.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06123274 | 2006-10-31 | ||
| PCT/EP2007/061253 WO2008052899A1 (en) | 2006-10-31 | 2007-10-22 | Ether derivatives dual modulators of the 5-ht2a and d3 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091675L true NO20091675L (no) | 2009-05-28 |
Family
ID=38962066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091675A NO20091675L (no) | 2006-10-31 | 2009-04-28 | Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7795437B2 (no) |
| EP (1) | EP2079693B1 (no) |
| JP (1) | JP5087631B2 (no) |
| KR (1) | KR101114651B1 (no) |
| CN (1) | CN101535258B (no) |
| AR (1) | AR063438A1 (no) |
| AU (1) | AU2007316249B2 (no) |
| BR (1) | BRPI0718127A2 (no) |
| CA (1) | CA2667511A1 (no) |
| CL (1) | CL2007003110A1 (no) |
| ES (1) | ES2401663T3 (no) |
| IL (1) | IL198157A0 (no) |
| MX (1) | MX2009004615A (no) |
| NO (1) | NO20091675L (no) |
| PE (1) | PE20081342A1 (no) |
| RU (1) | RU2009116509A (no) |
| TW (1) | TW200826940A (no) |
| WO (1) | WO2008052899A1 (no) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694009A1 (en) * | 2007-07-26 | 2009-01-29 | F. Hoffmann-La Roche Ag | Dual modulators of 5-ht2a and d3 receptors |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| WO2011060363A2 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8722683B2 (en) * | 2011-02-17 | 2014-05-13 | Hoffmann La-Roche Inc. | Benzodioxole piperazine compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1514718A (en) | 1974-08-15 | 1978-06-21 | Ferrosan Ab | Diphenyl-butylpiperidines |
| US4024264A (en) * | 1974-08-15 | 1977-05-17 | Ab Ferrosan | Diphenylbutylpiperidines |
| JP2860689B2 (ja) | 1990-03-14 | 1999-02-24 | 第一製薬株式会社 | ピリミジン誘導体 |
| EP0479601B1 (en) | 1990-10-05 | 1999-12-15 | Ajinomoto Co., Inc. | Piperidine derivatives and their use as antiarrhythmic agents |
| EE200100502A (et) | 1999-03-26 | 2002-12-16 | Astrazeneca Ab | Ühendid |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| HUP0103986A2 (hu) | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| CA2473892C (en) | 2001-12-04 | 2010-09-21 | Actelion Pharmaceuticals Ltd | Novel quinoline derivatives |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| AU2003303678A1 (en) | 2003-01-03 | 2004-08-10 | Genzyme Corporation | Urea derivatives and their use as anti-inflammatory agents |
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
-
2007
- 2007-10-22 EP EP07821617A patent/EP2079693B1/en not_active Not-in-force
- 2007-10-22 AU AU2007316249A patent/AU2007316249B2/en not_active Expired - Fee Related
- 2007-10-22 WO PCT/EP2007/061253 patent/WO2008052899A1/en not_active Ceased
- 2007-10-22 CA CA002667511A patent/CA2667511A1/en not_active Abandoned
- 2007-10-22 RU RU2009116509/04A patent/RU2009116509A/ru unknown
- 2007-10-22 US US11/876,007 patent/US7795437B2/en not_active Expired - Fee Related
- 2007-10-22 KR KR1020097008855A patent/KR101114651B1/ko not_active Expired - Fee Related
- 2007-10-22 ES ES07821617T patent/ES2401663T3/es active Active
- 2007-10-22 MX MX2009004615A patent/MX2009004615A/es active IP Right Grant
- 2007-10-22 JP JP2009535053A patent/JP5087631B2/ja not_active Expired - Fee Related
- 2007-10-22 BR BRPI0718127-2A2A patent/BRPI0718127A2/pt not_active IP Right Cessation
- 2007-10-22 CN CN2007800408979A patent/CN101535258B/zh not_active Expired - Fee Related
- 2007-10-29 AR ARP070104779A patent/AR063438A1/es unknown
- 2007-10-29 TW TW096140627A patent/TW200826940A/zh unknown
- 2007-10-29 CL CL200703110A patent/CL2007003110A1/es unknown
- 2007-10-31 PE PE2007001497A patent/PE20081342A1/es not_active Application Discontinuation
-
2009
- 2009-04-16 IL IL198157A patent/IL198157A0/en unknown
- 2009-04-28 NO NO20091675A patent/NO20091675L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007003110A1 (es) | 2008-06-13 |
| BRPI0718127A2 (pt) | 2014-02-18 |
| AR063438A1 (es) | 2009-01-28 |
| TW200826940A (en) | 2008-07-01 |
| KR101114651B1 (ko) | 2012-06-12 |
| JP5087631B2 (ja) | 2012-12-05 |
| PE20081342A1 (es) | 2008-09-18 |
| CA2667511A1 (en) | 2008-05-08 |
| CN101535258A (zh) | 2009-09-16 |
| MX2009004615A (es) | 2009-05-22 |
| AU2007316249A1 (en) | 2008-05-08 |
| RU2009116509A (ru) | 2010-12-10 |
| EP2079693A1 (en) | 2009-07-22 |
| KR20090075848A (ko) | 2009-07-09 |
| WO2008052899A1 (en) | 2008-05-08 |
| IL198157A0 (en) | 2009-12-24 |
| AU2007316249B2 (en) | 2013-01-24 |
| JP2010508319A (ja) | 2010-03-18 |
| CN101535258B (zh) | 2012-12-05 |
| ES2401663T3 (es) | 2013-04-23 |
| US20080103174A1 (en) | 2008-05-01 |
| EP2079693B1 (en) | 2013-02-27 |
| US7795437B2 (en) | 2010-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| NO20083197L (no) | Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese | |
| NO20091675L (no) | Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer | |
| MY148429A (en) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| DE502006006854D1 (de) | Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| NO20084530L (no) | Substituerte prolinamider, deres produksjon og anvendelse som medikament | |
| WO2007141283A3 (en) | Salts and crystalline salt forms of an 2-indolinone derivative | |
| MX2010008051A (es) | Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos. | |
| WO2008077557A8 (en) | 8-ethinylxanthine derivatives as selective a2a receptor antagonists | |
| WO2009123714A3 (en) | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor | |
| ATE523510T1 (de) | Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung | |
| MX2010001195A (es) | Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3. | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| ATE495159T1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| WO2008052088A8 (en) | Chromane derivatives, synthesis thereof, and intermediates thereto | |
| TW200738693A (en) | Substituted biaryls, process for their manufacture and use thereof as medicaments | |
| DE602007006643D1 (de) | Bis-1,2,3,4-tetrahydroisochinolinderivate und ihre verwendung als pharmazeutika | |
| NO20063602L (no) | Benzyl(iden)-laktam-derivater | |
| WO2008052078A3 (en) | Benzoxathiine and benzoxathiole derivatives and uses thereof | |
| MX2007010400A (es) | Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |